Imago BioSciences Management
Management criteria checks 2/4
Imago BioSciences' CEO is Hugh Rienhoff, appointed in Mar 2012, has a tenure of 10.83 years. total yearly compensation is $6.40M, comprised of 7.5% salary and 92.5% bonuses, including company stock and options. directly owns 1.48% of the company’s shares, worth $18.07M. The average tenure of the management team and the board of directors is 1.1 years and 3.3 years respectively.
Key information
Hugh Rienhoff
Chief executive officer
US$6.4m
Total compensation
| CEO salary percentage | 7.5% |
| CEO tenure | 10.8yrs |
| CEO ownership | 1.5% |
| Management average tenure | 1.1yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
Imago BioSciences (NASDAQ:IMGO) Is In A Good Position To Deliver On Growth Plans
Nov 08
Imago BioSciences GAAP EPS of -$0.41 beats by $0.09
Aug 12Here's Why We're Not Too Worried About Imago BioSciences' (NASDAQ:IMGO) Cash Burn Situation
Jul 26Companies Like Imago BioSciences (NASDAQ:IMGO) Are In A Position To Invest In Growth
Apr 12We're Not Very Worried About Imago BioSciences' (NASDAQ:IMGO) Cash Burn Rate
Dec 08CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2022 | n/a | n/a | -US$62m |
| Jun 30 2022 | n/a | n/a | -US$57m |
| Mar 31 2022 | n/a | n/a | -US$52m |
| Dec 31 2021 | US$6m | US$481k | -US$42m |
| Sep 30 2021 | n/a | n/a | -US$33m |
| Jun 30 2021 | n/a | n/a | -US$26m |
| Mar 31 2021 | n/a | n/a | -US$21m |
| Dec 31 2020 | US$733k | US$418k | -US$18m |
Compensation vs Market: Hugh's total compensation ($USD6.40M) is about average for companies of similar size in the US market ($USD5.11M).
Compensation vs Earnings: Hugh's compensation has increased whilst the company is unprofitable.
CEO
Hugh Rienhoff (69 yo)
10.8yrs
Tenure
US$6,397,318
Compensation
Dr. Hugh Young Rienhoff, Jr., M.D., serves as Chairman of the Board at Parvus Therapeutics Inc. since July 16, 2019. Dr. Rienhoff serves as a Managing Director of Life Science Venture Partners. He serves a...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 10.8yrs | US$6.40m | 1.48% $ 18.1m | |
| Chief Financial Officer | 1.3yrs | US$1.91m | 0.73% $ 8.9m | |
| Chief Operating & Business Officer | less than a year | no data | 0.15% $ 1.9m | |
| Senior VP of Finance & Principal Accounting Officer | less than a year | no data | 0.078% $ 955.6k | |
| Chief of Technical Operations | less than a year | US$428.49k | 0.42% $ 5.1m | |
| Global Head of Clinical Operations | 10.8yrs | US$423.39k | 0.44% $ 5.4m |
1.1yrs
Average Tenure
52yo
Average Age
Experienced Management: IMGO's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 10.8yrs | US$6.40m | 1.48% $ 18.1m | |
| Independent Chairman of the Board | 8.3yrs | US$38.80k | 0.077% $ 939.6k | |
| Independent Director | 1.2yrs | US$322.05k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$246.71k | 0% $ 0 | |
| Independent Director | 2.8yrs | US$247.41k | 0.0025% $ 30.7k | |
| Independent Director | 1.9yrs | US$559.65k | 0% $ 0 |
3.3yrs
Average Tenure
62.5yo
Average Age
Experienced Board: IMGO's board of directors are considered experienced (3.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/01/12 14:29 |
| End of Day Share Price | 2023/01/10 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Imago BioSciences, Inc. is covered by 6 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Schmidt | Guggenheim Securities, LLC |
| Mitchell Kapoor | H.C. Wainwright & Co. |
| Maurice Raycroft | Jefferies LLC |